Study of Danicopan in Participants With Hepatic Impairment
A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects
Sponsor: Achillion, a wholly owned subsidiary of Alexion
Listed as NCT03555539, this PHASE1 trial focuses on Hepatic Impairment and remains completed. Sponsored by Achillion, a wholly owned subsidiary of Alexion, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Nov 2023 [monthly]
Completed PHASE1
-
Sep 2021 — Apr 2023 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2019 — Jun 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Achillion, a wholly owned subsidiary of Alexion
- Alexion Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .